Using a Myc-based lymphoma model, we had previously shown that LMP2A accelerates Myc-induced lymphomagenesis (78, 79) and that targeting LMP2A-modulated cellular kinases in this model was efficacious (19, 20), encouraging our current studies exploring a new SYK inhibitor. The gene discussed is MYC; the disease is lymphoma.